18,573 Shares in Natera, Inc. (NASDAQ:NTRA) Purchased by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 18,573 shares of the medical research company's stock, valued at approximately $2,940,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its holdings in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after buying an additional 97 shares during the last quarter. Versant Capital Management Inc increased its position in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after acquiring an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares during the period. Principal Securities Inc. boosted its stake in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after acquiring an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC grew its holdings in Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Michael Burkes Brophy sold 43,502 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $176.88, for a total transaction of $7,694,633.76. Following the transaction, the chief financial officer now directly owns 70,629 shares of the company's stock, valued at approximately $12,492,857.52. This trade represents a 38.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 6,980 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $150.10, for a total value of $1,047,698.00. Following the completion of the sale, the chief executive officer now directly owns 185,182 shares of the company's stock, valued at approximately $27,795,818.20. This trade represents a 3.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 196,601 shares of company stock valued at $29,831,575. 7.60% of the stock is currently owned by corporate insiders.

Natera Price Performance

Shares of NASDAQ:NTRA traded up $5.30 during trading on Friday, reaching $156.66. The company had a trading volume of 1,072,062 shares, compared to its average volume of 1,382,188. The company has a fifty day moving average of $146.93 and a two-hundred day moving average of $154.18. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $21.18 billion, a P/E ratio of -89.01 and a beta of 1.80. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on NTRA shares. The Goldman Sachs Group upped their price target on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Royal Bank of Canada assumed coverage on shares of Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective on the stock. BTIG Research reiterated a "buy" rating on shares of Natera in a research note on Friday, February 28th. Sanford C. Bernstein upped their price target on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research note on Friday, January 10th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $175.76.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.